Search the Newsreel

SEPN|Septerna Inc|Price:33.660|Chg%:-0.310

This article provides a comprehensive stock analysis of Septerna Inc (SEPN), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a clinical-stage biotechnology firm, is developing GPCR oral small-molecule drugs with a pipeline focused …

Septerna Inc (SEPN) Institutional Confidence

Septerna Inc (SEPN) has an institutional shareholding score of 10.00, placing it first among 384 companies in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 106.37%, a 5.10% quarter-over-quarter increase. John Hussman is the largest institutional shareholder, holding 84.59K shares, …

Septerna Inc (SEPN) Financial Health: Profitability & Balance Sheet Analysis

Septerna Inc (SEPN) currently holds a financial score of 8.65, positioning it at 35 out of 385 in the Biotechnology & Medical Research industry, reflecting a weak financial status but high operating efficiency. The company reported a significant year-over-year revenue increase of 12010.96% to …

SEPN|Septerna Inc|Price:35.017|Chg%:+1.407

Septerna Inc. (SEPN) is a clinical-stage biotechnology company focused on developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline addresses endocrinology, immunology, inflammation, and metabolic diseases, and it aims to discover novel treatments for unmet …

Septerna Inc (SEPN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Septerna Inc (SEPN), detailing its business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant financial data necessary for this analysis. Consequently, the report states that information …

Septerna Inc (SEPN) Valuation: PE, PB & Fair Value Analysis

Septerna Inc (SEPN) has a current valuation score of 8.48, placing it 126th out of 386 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -41.42, which is significantly below its recent high and slightly above its recent low. …

Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Brokerages

Septerna, Inc. (NASDAQ:SEPN) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $45.89, exceeding its current stock price of $33.49. The company reported better-than-expected quarterly results, with a loss of $0.19 per share against an estimated $0.42 …

Septerna Inc (SEPN) Income Statement

This article provides the quarterly and annual income statements for Septerna Inc (SEPN), detailing its financial performance. It includes key figures such as total revenue, operating expenses, net income, and earnings per share, alongside year-over-year comparisons. The data from FY2023Q3 through FY2026Q1 allows investors …

SEPN Cash Flow Statement

This article provides the quarterly cash flow statement for Septerna Inc. (SEPN), detailing its operating, investing, and financing cash flows from FY2023Q4 to FY2026Q1. It also includes an overview of key cash flow metrics for the company, such as operating cash flow, capital expenditures, …

Septerna (SEPN) president sells 4,000 shares and exercises 4,000 options under plan

Elizabeth Bhatt, President and COO of Septerna, Inc. (SEPN), reported transactions on July 15, 2026, involving the exercise of 4,000 stock options at $6.81 per share and the sale of 4,000 shares at a weighted average price of $33.9935 per share. These sales were …

Septerna president & COO Elizabeth Bhatt sells $135,974 in stock

Septerna's President and COO, Elizabeth Bhatt, sold 4,000 shares of company stock for $135,974 shortly after exercising stock options on the same day. The sale was executed under a Rule 10b5-1 plan established in October 2025. This transaction follows a significant 165% stock surge …

Form 4 Septerna Inc For: 17 July By Investing.com

This article from Investing.com announces the filing of Form 4 for Septerna Inc. on July 17. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders whenever they buy or sell shares of their …

[144] Septerna, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Septerna, Inc. (SEPN) on July 15, 2026. The filing indicates a proposed sale of 4000 shares of common stock with an aggregate market value of $138,160.00, acquired through the exercise of stock options. The …

Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?

Party Time: Brokers Just Made Major Increases To Their Septerna, Inc. (NASDAQ:SEPN) Earnings Forecasts

Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates

Septerna, Inc. Common Stock (SEPN) Stock Forecast & Price Prediction 2026–2030